Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-08-14
2007-08-14
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S130100, C424S178100, C503S223000, C503S223000, C503S223000
Reexamination Certificate
active
10927433
ABSTRACT:
The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5482040 (1996-01-01), Martin, Jr.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6333405 (2001-12-01), Anderson et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 2131355 (1996-03-01), None
patent: 2068593 (2003-07-01), None
patent: 0239400 (1987-09-01), None
patent: 0365997 (1990-05-01), None
patent: WO 89/00692 (1989-01-01), None
patent: WO 89/01783 (1989-03-01), None
patent: WO 90/04410 (1990-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/12231 (1993-06-01), None
patent: WO 96/13594 (1996-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 98/18809 (1998-05-01), None
patent: WO 99/43816 (1999-09-01), None
patent: WO 00/26394 (2000-05-01), None
patent: WO 2004/003155 (2004-01-01), None
Abergel et al., “Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab',”Proteins: Structure, Function, and Genetics17:438-443, 1993.
Colcher et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies,”Cancer Research48:4597-4603, 1988.
Divgi et al., “Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen,”Nucl. Med. Biol.21(1):9-15, 1994.
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys,”J. Immunol.147:1352-1359, 1991.
Hand et al., “Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma,”Cancer Supplement73(3):1105-1113, 1994.
Iwahashi et al., “CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity,”Molecular Immunology36:1079-1091, 1999.
Johnson et al., “Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3,”Cancer Research46:850-857, 1986.
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525, 1986.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol.38:3-16, 2001.
Kashmiri et al., “Generation, Characterization, and in Vivo Studies of Humanized Anticarcinoma Antibody CC49,”Hybridoma14(5):461-473, 1995.
Mulligan et al., “Phase I Study of Intravenous177Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma,”Clinical Cancer Research1:1447-1454, 1995.
Muraro et al., “Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen,”Cancer Research48:4588-4596, 1988.
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties,”Molecular Immunology28(4/5):489-498, 1991.
Padlan, “Anatomy of the antibody molecule,”Mol. Immunol.31:169-217, 1994.
Padlan et al., “Identification of Specificity-determining Residues in Antibodies,”The FASEB Journal9:133-139, 1995.
Paul,Fundamental Immunology,Raven Press, NY, Ch. 8, p. 242, 1993.
Reichman et al., “Reshaping human antibodies for therapy,”Nature(London) 332:323-327, 1988.
Rixon et al., “Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies,”The Journal of Immunology151(11):6559-6568, 1993.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”PNAS79(6):1979-1983, 1982.
Saldanha et al., “A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells,”Mol. Immunol.36:709-719, 1999.
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J. Mol. Biol.263:551-567, 1996.
Sha et al., “A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen,”Cancer Biotherapy9(4):341-349, 1994.
Sharkey et al., “Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies,”Cancer Res.55:5935s-5945s.
Slavin-Chiorini et al., “A CDR-grafted (humanized) domain-deleted antitumor antibody,”Cancer Biother. Radiopharm.12:305-316, 1997.
Slavin-Chiorini et al., “Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins,”Cancer Research(Supplement) 55:5957s-5967s, 1995.
Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,”Journal of Immunology164(3):1432-1441, 2000.
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,”J. Mol. Biol.294:151-162, 1999.
Xiang et al., “The Tyrosine Residue at Position 97 in the VHCDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen,”Cancer Biotherapy8(3):253-262, 1993.
Xiang et al., “Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction,”Protein Engineering9(6):539-543, 1996.
Xiang et al., “Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding,”Protein Eng.12:417-421, 1999.
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Mol. Immunol.,40:337-349, 2003.
Kashmiri et al., Chapter 21 inMethods in Molecular Biology, vol. 248: Antibody Engineering: Methods and Protocols,p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003.
Kashmiri et al., “SDR grafting—a new approach to antibody humanization,”Methods,36:25-34, 2005.
Pascalis et al., “In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants,”Clinical Cancer Research,9:5521-5531, 2003.
Kashmiri Syed V. S.
Padlan Eduardo A.
Schlom Jeffrey
Helms Larry R.
Klarquist & Sparkman, LLP
Tungaturthi Parithosh K.
United States of America as represented by the Secretary of the
LandOfFree
Variants of humanized anti-carcinoma monoclonal antibody CC49 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of humanized anti-carcinoma monoclonal antibody CC49, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of humanized anti-carcinoma monoclonal antibody CC49 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3867562